

# Leukaemia Section

## Short Communication

### t(16;21)(q24;q22)

Christine Pérot

Laboratoire de Cytogénétique, Hôpital Saint-Antoine, Paris, France

Published in Atlas Database: April 1998

Online updated version: <http://AtlasGeneticsOncology.org/Anomalies/t1621ID1123.html>

DOI: 10.4267/2042/37444

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.  
© 1998 *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

## Clinics and pathology

### Disease

ANLL and therapy related ANLL; mainly with preceding MDS.

### Phenotype / cell stem origin

M1 or M2 ANLL.

### Epidemiology

Rare: five available cases herein reviewed, 4 adults (42-70 yrs) and one child; 1M/4F.

### Clinics

Blood data: pancytopenia.

### Prognosis

Very poor: all patients died within a year (2 days-12 mths).

## Cytogenetics

### Additional anomalies

Found in three cases; +8 twice.

## Genes involved and Proteins

### AML1's partner is still unknown

Location: 16q24

### AML1

Location: 21q22

### DNA / RNA

Transcription is from telomere to centromere.

### Protein

Contains a Runt domain and, in the C-term, a transactivation domain; forms heterodimers; widely expressed; nuclear localisation; transcription factor (activator) for various hematopoietic-specific genes.

## References

Berger R, Le Coniat M, Romana SP, Jonveaux P. Secondary acute myeloblastic leukemia with t(16;21)(q24;q22) involving the AML1 gene. *Hematol Cell Ther* 1996;38:183-186.

Shimada M, Ohtsuka E, Shimizu T, Matsumoto T, Matsushita K, Tanimoto F, Kajii T. A recurrent translocation, t(16;21)(q24;q22), associated with acute myelogenous leukemia: identification by fluorescence in situ hybridization. *Cancer Genet Cytogenet* 1997;96:102-105.

---

*This article should be referenced as such:*

Pérot C. t(16;21)(q24;q22). *Atlas Genet Cytogenet Oncol Haematol*.1998;2(3):104.

---